Health Economics›Immune thrombocytopenia›Relapsed or refractory

Relapsed or refractory

Immune thrombocytopenia · 13 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Dexamethasone and Rituximab Variant #01	—	R 52 504	14d	—	—	~3	~R 105 702 indirect	—
Eltrombopag monotherapy Variant #01	—	R 44 339	28d	—	—	~2	~R 88 677 indirect	—
Cyclosporine monotherapy Variant #03	—	R 29 855	—	—	—	~1	~R 29 855 indirect	—
ATRA and Danazol Variant #01	—	R 16 221	112d	—	—	~1	~R 16 221 indirect	—
Danazol monotherapy Variant #01	—	R 1 870	112d	—	—	~1	~R 1 870 indirect	—
Mycophenolate mofetil monotherapy Variant #01	—	R 1 356	28d	—	—	~2	~R 2 713 indirect	—
Dexamethasone monotherapy Variant #03	—	R 1 215	28d	—	—	~4	~R 4 861 indirect	—
Romiplostim monotherapy Variant #01	—	R 2	7d	—	—	~2	~R 5 indirect	—
Rituximab monotherapy Variant #09 Partial	—	—	28d	~20.3 mo	—	~1	—	20
Vinblastine-loaded platelets Partial	—	—	—	—	—	—	—	—
Placebo Partial	—	—	—	~4.2 mo	~8.0 mo	—	—	145
Fostamatinib monotherapy Variant #01 Partial	—	—	168d	—	—	~1	—	—
Avatrombopag monotherapy Variant #01 Partial	—	—	5d	—	—	~2	—	—

13 of 13 regimens shown